Life Sciences Investors Talk Shop On Asia Opportunities – Singapore Conference
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - The swing from big pharma to biotech has captured investor attention, and has changed the nature of the types of investments that venture capitalists are making. Many are willing to take bigger risks in Asia and are opting in earlier rather than as pipelines mature, making intellectual property protection even more critical, a panel of investors said during the BioMedical Asia 2008 conference in Singapore April 15
You may also be interested in...
Novartis Venture Fund Supporting Korea's Bio Start-ups
Series B financing for the fund's first investment is seen by Novartis as validation for discovery efforts.
Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences
Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences